Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class (Ascending) Administration Route Package Effective Date Package Discontinuation Date Status
00703-4502-94 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Feb. 9, 2015 July 31, 2020 In Use
00703-4502-93 00703-4502 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Sept. 4, 2024 In Use
00409-3414-01 00409-3414 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Feb. 2, 2006 In Use
00409-3414-11 00409-3414 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Aug. 26, 2024 In Use
00409-5255-25 00409-5255 Metoclopramide Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Nov. 14, 2022 In Use
52584-0414-01 52584-0414 Metoclopramide Hydrochloride Metoclopramide 5.0 mg/mL Ancillary Therapy Antiemetic Dopamine-2 Receptor Antagonist Intramuscular, Intravenous Sept. 13, 2016 May 1, 2023 No Longer Used
50242-0062-01 50242-0062 Erlotinib Hydrochloride Tarceva 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2005 In Use
50242-0063-01 50242-0063 Erlotinib Hydrochloride Tarceva 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2005 In Use
50242-0064-01 50242-0064 Erlotinib Hydrochloride Tarceva 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral April 30, 2005 In Use
54868-5290-00 54868-5290 Erlotinib Hydrochloride Tarceva 25.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 1, 2005 In Use
54868-5447-00 54868-5447 Erlotinib Hydrochloride Tarceva 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 13, 2005 In Use
00002-7716-01 00002-7716 Necitumumab Portrazza 16.0 mg/mL Immunotherapy Monoclonal Antibody EGFR Intravenous Nov. 24, 2015 In Use
55513-0954-01 55513-0954 Panitumumab Vectibix 100.0 mg/5mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct. 10, 2006 In Use
55513-0956-01 55513-0956 Panitumumab Vectibix 400.0 mg/20mL Immunotherapy Monoclonal Antibody EGFR Intravenous Oct. 10, 2006 In Use
00069-0197-30 00069-0197 dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
00069-2299-30 00069-2299 dacomitinib Vizimpro 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
00597-0137-30 00597-0137 Afatinib Gilotrif 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 9, 2013 In Use
00597-0137-90 00597-0137 Afatinib Gilotrif 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 1, 2018 In Use
00597-0138-30 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 8, 2013 In Use
00597-0138-95 00597-0138 Afatinib Gilotrif 40.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug. 8, 2013 In Use
00093-7663-56 00093-7663 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 In Use
00093-7664-56 00093-7664 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral May 9, 2019 In Use
00069-1198-30 00069-1198 dacomitinib Vizimpro 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
00310-0482-30 00310-0482 Gefitinib IRESSA 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 13, 2015 In Use
00310-0482-93 00310-0482 Gefitinib IRESSA 250.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral July 25, 2016 Aug. 31, 2019 In Use

Found 10,000 results in 8 milliseconds — Export these results